Skip to main content
Equibles

DEUTSCHE BANK AG\

Bank

Position in AKTS — Aktis Oncology, Inc.

CIK 948046 FRANKFURT AM MAIN, 2M
Back to AKTS Full portfolio

Position in AKTS

as of Jun 30, 2026 · filed Aug 7, 2026
Position Value
$677,538
+$425,648 QoQ
Shares Held
21,022
+49.3% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#58
of 114 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 1% Shared 0% None 99%

Common Shares in AKTS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

DEUTSCHE BANK AG\ holds $3,199,137,357 across 296 Biotechnology names. AKTS ranks #166 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 1,579,110 $784,391,303
2 REGN
Regeneron Pharmaceuticals, Inc.
 518,409 $323,248,743
3 ALNY
Alnylam Pharmaceuticals, Inc.
 815,400 $245,459,858
4 RVMD
Revolution Medicines, Inc.
 888,019 $166,308,196
5 RPRX
Royalty Pharma plc
 2,717,951 $152,395,510
6 INCY
Incyte Corp
 1,262,988 $143,172,312
7 ARGX
Argenx SE
 137,335 $127,415,291
8 LGND
Ligand Pharmaceuticals Inc
 249,611 $78,899,539

All Filings in AKTS

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $677,538 21,022
2026-03-31 $251,890 14,080